Allergy and allergic diseases. First of two parts. N Engl J Med 2001; 344:30–7. .
Functional and structural characterization of P40, a mouse glycoprotein with T-cell growth factor activity. Proc Natl Acad Sci USA 1988; 85:6934–8. , , .
Cloning and characterization of a cDNA for a new mouse T cell growth factor (P40). J Exp Med 1989; 169:363–8. , , , , , , , .
Mast cell growth-enhancing activity (MEA) is structurally related and functionally identical to the novel mouse T cell growth factor P40/TCGFIII (interleukin 9). Eur J Immunol 1990; 20:1413–16. , , , , , , , .
Interleukin-9 is a major anti-apoptotic factor for thymic lymphomas. Blood 1995; 85:1300–5. , , , .
et al. Transforming growth factor-beta ‘reprograms’ the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol 2008; 9:1341–6. , ,
et al. IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(−) effector T cells. Nat Immunol 2008; 9:1347–55. , ,
et al. Interleukin-9 potentiates the interleukin-4-induced immunoglobulin (IgG, IgM and IgE) production by normal human B lymphocytes. Eur J Immunol 1993; 23:1687–92. , ,
Interleukin-9 potentiates the interleukin-4-induced IgE and IgG1 release from murine B lymphocytes. Immunology 1993; 79:146–51. , , , .
IL-4-independent regulation of in vivo IL-9 expression. J Immunol 1997; 159:2616–23. , , , , , .
et al. IL-9 and its receptor in allergic and nonallergic lung disease: increased expression in asthma. J Allergy Clin Immunol 2000; 105:108–15. , ,
Increased expression of interleukin-9 messenger RNA after segmental allergen challenge in allergic asthmatics. Chest 2003; 123(Suppl. 3):370S. , , , , , , .
Segmental allergen challenge in patients with atopic asthma leads to increased IL-9 expression in bronchoalveolar lavage fluid lymphocytes. J Allergy Clin Immunol 2003; 111:1319–27. , , , , , , .
et al. Involvement of IL-9 in the bronchial phenotype of patients with nasal polyposis. J Allergy Clin Immunol 2004; 113:462–9. , ,
et al. Expression of interleukin-9 leads to Th2 cytokine-dominated responses and fatal enteropathy in mice with chronic Schistosoma mansoni infections. Infect Immun 2000; 68:6005–11. , ,
Interleukin-9 enhances resistance to the intestinal nematode Trichuris muris. Infect Immun 1998; 66:3832–40. , , , .
A primary intestinal helminthic infection rapidly induces a gut-associated elevation of Th2-associated cytokines and IL-3. J Immunol 1993; 1:3434–41. , , , , , , , .
Human P40/IL-9. Expression in activated CD4+ T cells, genomic organization, and comparison with the mouse gene. J Immunol 1990; 144:4235–41. , , , , , .
IL-2 dependence of IL-9 expression in human T lymphocytes. J Immunol 1992; 148:3147–51. , , , .
IL-2-induced IL-9 production by allergen-specific human helper T-cell clones. Int Arch Allergy Immunol 2007; 143(Suppl. 1):71–5. , , , , , .
A cascade of cytokines is responsible for IL-9 expression in human T cells. Involvement of IL-2, IL-4, and IL-10. J Immunol 1995; 154:2624–30. , , , , , , .
et al. CCR8 expression identifies CD4 memory T cells enriched for FOXP3+ regulatory and Th2 effector lymphocytes. J Immunol 2006; 177:6940–51. , ,
et al. Induction of the IL-9 gene by HTLV-I Tax stimulates the spontaneous proliferation of primary adult T-cell leukemia cells by a paracrine mechanism. Blood 2008; 111:5163–72. , ,
IL-1 serves as a secondary signal for IL-9 expression. J Immunol 1991; 147:3848–54. , , , , , , .
Interleukin 1 plays a major role in the development of Th2-mediated immunity. Eur J Immunol 2004; 34:3674–81. , .
et al. IL-9 production of naive CD4+ T cells depends on IL-2, is synergistically enhanced by a combination of TGF-beta and IL-4, and is inhibited by IFN-gamma. J Immunol 1994; 153:3989–96. , ,
Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 1993; 362:245–8. , , , , , .
Differential regulation of IL-9-expression after infection with Leishmania major in susceptible and resistant mice. Immunobiology 1993; 189:419–35. , , .
Regulation of Th2 differentiation and Il4 locus accessibility. Annu Rev Immunol 2006; 24:607–56. , , , .
The lineage decisions of helper T cells. Nat Rev Immunol 2002; 2:933–44. , .
A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000; 100:655–69. , , , , , .
IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007; 25:821–52. , , , .
Regulatory T cells and immune tolerance. Cell 2008; 133:775–87. , , , .
The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 1998; 16:495–521. , , , , , , .
Regulation of the IL-12/IL-12R axis: a critical step in T-helper cell differentiation and effector function. Immunol Rev 1999; 170:65–72. , , , .
T-bet is a STAT1-induced regulator of IL-12R expression in naive CD4+ T cells. Nat Immunol 2002; 3:549–57. , , , , , , , .
GATA-3 promotes Th2 responses through three different mechanisms: induction of Th2 cytokine production, selective growth of Th2 cells and inhibition of Th1 cell-specific factors. Cell Res 2006; 16:3–10. , , , , .
Signaling mechanisms, interaction partners, and target genes of STAT6. Cytokine Growth Factor Rev 2006; 17:173–88. , , , .
Th17 cells: a new fate for differentiating helper T cells. Immunol Res 2008; 41:87–102. , .
Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation. Semin Immunol 2007; 19:400–8. , , .
Conversion of peripheral CD4+ CD25− naive T cells to CD4+ CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198:1875–86. , , , , , , , .
et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 2008; 29:44–56. , ,
Cutting edge: regulatory T cells induce CD4+ CD25− Foxp3− T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-beta. J Immunol 2007; 178:6725–9. , , , .
Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 2007; 317:256–60. , , , , , , .
Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci USA 2009; 106:1903–8. , , , , , .
et al. Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells. Immunity 2009; 30:155–67. , ,
et al. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 2006; 442:997–1002. , ,
Neuron-mediated generation of regulatory T cells from encephalitogenic T cells suppresses EAE. Nat Med 2006; 12:518–25. , , , .
Multiple transcription factors are required for activation of human interleukin 9 gene in T cells. J Biol Chem 1996; 271:15815–22. , , , , , .
et al. p38 MAP kinase drives the expression of mast cell-derived IL-9 via activation of the transcription factor GATA-1. Mol Immunol 2007; 44:926–33. , ,
Molecular organization of the cytokine gene cluster, involving the human IL-3, IL-4, IL-5, and GM-CSF genes, on human chromosome 5. Blood 1989; 73:1142–8. , , , .
Genetic susceptibility to asthma–bronchial hyperresponsiveness coinherited with a major gene for atopy. N Engl J Med 1995; 333:894–900. , , , , , , , .
et al. Evidence for linkage between asthma/atopy in childhood and chromosome 5q31–q33 in a Japanese population. Am J Respir Crit Care Med 1997; 156:1390–3. , ,
Allelic association of gene markers on chromosomes 5q and 11q with atopy and bronchial hyperresponsiveness. Am J Respir Crit Care Med 1996; 1:1280–4. , , , , , , , .
et al. Interleukin 9: a candidate gene for asthma. Proc Natl Acad Sci USA 1997; 94:13175–80. , ,
et al. Asthma and bronchial hyperresponsiveness linked to the XY long arm pseudoautosomal region. Genomics 1998; 52:233–5. , ,
Asthma. N Engl J Med 2001; 344:350–62. , .
et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992; 326:298–304. , ,
IL-13 expression at the sites of allergen challenge in patients with asthma. J Immunol 1995; 155:2688–94. , , , , , , .
Elevated expression of interleukin-9 mRNA in the bronchial mucosa of atopic asthmatics and allergen-induced cutaneous late-phase reaction: relationships to eosinophils, mast cells and T lymphocytes. Clin Exp Allergy 2002; 32:866–71. , , , .
Allergen-induced interleukin-9 production in vitro: correlation with atopy in human adults and comparison with interleukin-5 and interleukin-13. Clin Exp Allergy 2006; 36:174–82. , , , , , .
IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: effect of immunotherapy. J Allergy Clin Immunol 2005; 116:73–9. , , , , .
et al. Interleukin-9 promotes allergen-induced eosinophilic inflammation and airway hyperresponsiveness in transgenic mice. Am J Respir Cell Mol Biol 1998; 19:713–20. , ,
Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. J Exp Med 1998; 188:1307–20. , , , .
IL-9-deficient mice establish fundamental roles for IL-9 in pulmonary mastocytosis and goblet cell hyperplasia but not T cell development. Immunity 2000; 13:573–83. , , , , , .
The absence of interleukin 9 does not affect the development of allergen-induced pulmonary inflammation nor airway hyperreactivity. J Exp Med 2002; 195:51–7. , , , , .
et al. Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. Am J Respir Crit Care Med 2002; 166:409–16. , ,
IL-9 promotes but is not necessary for systemic anaphylaxis. J Immunol 2005; 175:335–41. , , , .
et al. IL-9- and mast cell-mediated intestinal permeability predisposes to oral antigen hypersensitivity. J Exp Med 2008; 205:897–913. , ,
Cytokines and growth factors in airway remodeling in asthma. Curr Opin Immunol 2007; 19:676–80. , .
Mucus hypersecretion in asthma: causes and effects. Curr Opin Pulm Med 2009; 15:4–11. , , , .
et al. Allergen-induced IL-9 directly stimulates mucin transcription in respiratory epithelial cells. J Clin Invest 1999; 104:1375–82. , ,
Interleukin-9 induces mucous cell metaplasia independent of inflammation. Am J Respir Cell Mol Biol 2003; 28:664–72. , , , , , , , .
Interleukin-9 induces goblet cell hyperplasia during repair of human airway epithelia. Am J Respir Cell Mol Biol 2003; 28:286–95. , , , , .
Interleukin-9 upregulates mucus expression in the airways. Am J Respir Cell Mol Biol 2000; 22:649–56. , , , , , , .
et al. IL-13 mediates in vivo IL-9 activities on lung epithelial cells but not on hematopoietic cells. J Immunol 2007; 178:3244–51. , ,
Cytokine regulation of mucus production in a model of allergic asthma. Novartis Found Symp 2002; 20:77–82. , , , .
Profibrotic effect of IL-9 overexpression in a model of airway remodeling. Am J Respir Cell Mol Biol 2007; 37:202–9. , , , , , , .
Interleukin-9 influences chemokine release in airway smooth muscle: role of ERK. Am J Physiol Lung Cell Mol Physiol 2003; 284:L1093–102. , , , , , , , .
IL-9-mediated induction of eotaxin1/CCL11 in human airway smooth muscle cells. J Immunol 2004; 173:2771–9. , , , , , .
et al. Transgenic overexpression of interleukin (IL)-10 in the lung causes mucus metaplasia, tissue inflammation, and airway remodeling via IL-13-dependent and -independent pathways. J Biol Chem 2002; 277:35466–74. , ,
CD4+ cells are required for chronic eosinophilic lung inflammation but not airway remodeling. Am J Physiol Lung Cell Mol Physiol 2009; 296:L229–35. , , , .
The contribution of transforming growth factor-beta and epidermal growth factor signalling to airway remodelling in chronic asthma. Eur Respir J 2006; 27:208–29. , , .
IL-9 in allergic inflammation. Int Arch Allergy Immunol 2004; 134:79–87. , , .
Role of IL-9 in the pathophysiology of allergic diseases. J Allergy Clin Immunol 2001; 107:575–82. , , .